Everest Organics
- Market cap
- ₹ 216 Cr.
- P/E
- 48.9x
- P/B
- 3.19x
- 52-week range
- 197 – 536.4
- ROE
- 8%
- ROCE
- 12%
- Debt / equity
- 0.68
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Everest Organics against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)48.9 against a typical 34.3: pricier than most peers (1st = cheapest).153rd of 220
- Sales growth−10% against a typical +15.6% from a year earlier.164th of 197
- Profit growth−21.3% against a typical +18.9% from a year earlier.115th of 160
- Share price, 3 months−14.1% against a typical −0.5%.162nd of 200
- Size₹ 216.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).114th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 53 | 53 | 32 | 44 | 42 | 41 | 54 | 51 | 43 | 49 | 48 |
| Expenses | 47 | 50 | 50 | 36 | 41 | 38 | 37 | 49 | 46 | 39 | 42 | 44 |
| Operating Profit | 3 | 3 | 3 | −4 | 3 | 4 | 3 | 4 | 5 | 4 | 7 | 4 |
| OPM % | 5.5% | 5.3% | 5.6% | −11.3% | 7.8% | 9.6% | 8.4% | 8.3% | 10.1% | 8.3% | 13.7% | 8.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 |
| Depreciation | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | −6 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 |
| Tax % | 78.6% | 93.3% | 62.5% | 0% | 1.3% | 0.9% | −206.3% | 35.2% | 56.9% | 65.4% | −21.2% | 26.8% |
| Net Profit | 0 | 0 | 0 | −6 | 1 | 1 | 3 | 1 | 1 | 0 | 3 | 1 |
| EPS in Rs | 0.04 | 0.02 | 0.08 | −7.61 | 0.92 | 1.42 | 3 | 1.45 | 1.19 | 0.37 | 2.71 | 1.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- 2%
- TTM
- 5%
- 10 Years
- 21%
- 5 Years
- −17%
- 3 Years
- 315%
- TTM
- −15%
- 10 Years
- 20%
- 5 Years
- 0%
- 3 Years
- 36%
- TTM
- —
- 10 Years
- 10%
- 5 Years
- 2%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Everest Organics | ₹ 258.00 | ₹ 216 Cr. | 48.9x | 3.2x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sirisha Sri Kakarlapudi
- Chief Executive Officer, Managing Director, Executive Director
- P. Ramakrishna
- Chief Financial Officer
- M. Bangara Raju
- Executive Independent Director, Director - Human Resources, Legal & Corporate Affairs
- Srikakarlapudi Harikrishna
- Whole-time Director
- S.K.Hari Krishna
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.